Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine is well-positioned for durable growth because its Swoop platform is gaining traction across hospitals, neurology offices, and international markets, with more than 200 systems deployed worldwide and 12 units sold in 2Q26, up from 8 a year earlier. Its appeal is strengthened by a compelling 1- to 1.5-year hospital ROI, rising utilization, minimal pricing resistance, and expanding clinical utility from next-generation Model 2 hardware and recurring FDA-cleared Optive AI software updates. Financially, the company has posted gross margins above 50% for four consecutive quarters, reported $3.9M of 2Q26 revenue and $43.5M in cash, and is targeting $20M-$22M of revenue in FY26 with cash burn declining toward $26M-$28M.

Hyperfine is facing a fragile commercial setup because its Model 2 ramp is still early, its install base remains relatively small, and quarterly results can be lumpy if adoption or install timing slips. The business also carries multiple execution risks that could pressure fundamentals, including future capital needs, regulatory clearances, reimbursement updates, supplier pricing pressure from a limited vendor base with a single-source magnet supplier, and competitive pressure from larger MRI players. Although the guidance midpoint implies only a ~10% y/y reduction in cash burn and the company is targeting a large >$16B U.S. market, weak operating leverage, financing dependence, and international/geopolitical risk keep the outlook negative.